We’re back at Bventure! Cancerappy is actively participating in this innovation event through the University of Deusto, joining the roundtable discussion, “The Value of Talent in an AI Startup.” On Tuesday, Oct 15th, our CEO will share insights on how AI is impacting our work and driving progress in our field. Don’t miss it!
We are glad to announce that Luis Martin, the Chief Executive Officer of CancerAppy, will be presenting at the ACCESS CHINA Partnering Forum – Autumn Virtual Showcase during September 24th to 25th, and 27th, 2024. ACCESS CHINA Biotech Forum is the largest corporate access event between Asia and the western biopharma industry.
A Cancerappy delegation has participated in a roadshow of European companies to learn about the innovative health ecosystem in the Shanghai and Wuxi area.
Our CEO has had the opportunity to hold various meetings with different agents of the innovation ecosystem, especially in the health sector, including investors, local government officials, leaders of research and innovation centers, as well as biotech companies and laboratories.
We have been able to observe first-hand how China has evolved to reach a peak of technological innovation in the health sector that is enviable and leading in the world.
From all these meetings, we have achieved several collaboration agreements that represent the beginning of a great business adventure that Cancerappy is going to begin imminently.
We are proud to announce our significant contribution to a seminal scientific paper focused on Antibody-Drug Conjugates (ADCs) in the clinical landscape. The paper delves, among other aspects, into an extensive analysis of the physicochemical properties of ADC payloads, yielding crucial insights pivotal for the strategic design and advancement of ADC therapies.
As a leader in innovative biotechnological solutions, CancerAppy team played a high relevant role in the collaborative effort that culminated in this comprehensive examination. The paper’s findings promise to revolutionize the development and optimization of ADCs, offering a clearer understanding of the relationship between payload properties and therapeutic efficacy.
ADCs represent a pivotal therapeutic advancement, effectively applied across diverse clinical scenarios. Comprising antibodies targeting tumor-associated antigens (TAAs), cytotoxic payloads, and binding linkers, ADCs have primarily focused research on target identification, antibody design, and linker optimization, leaving other critical clinical facets understudied. In this work, the researches performed a comprehensive assessment of approved ADCs and analyzed properties such as payload physicochemical attributes, potency, drug antibody ratio (DAR), exposure–response correlations, and development strategies. Optimal clinical candidates feature ideal payload properties and cleavable linkers, particularly impactful in low TAA expression contexts. Additionally, early clinical tactics, including altered dosing schedules, aim for enhanced efficiency. This analysis emphasizes overlooked facets essential for ADC cancer development, proposing avenues for refinement.
Dr. Elisa Poyatos, Chief Scientific Officer at CancerAppy, expressed enthusiasm about the company’s involvement in this groundbreaking endeavor, stating, “Our team’s commitment to pushing the boundaries of scientific knowledge has motivated our dive into the intricate details of ADCs. By conducting thorough analysis and partnering with respected researchers, we’ve uncovered crucial understandings about the physicochemical characteristics of ADC payloads. This knowledge might empower the industry to create therapies that are more effective and impactful.”
This collaborative scientific effort underscores CancerAppy’s commitment to pioneering advancements in biotechnology and reinforces its dedication to fostering innovation within the industry.
The complete work has been published in the Journal of Hematology & Oncology, with an impact factor of 28.5 (2022); and can be read with open access at the following link: https://jhoonline.biomedcentral.com/articles/10.1186/s13045-023-01519-0
For media inquiries, please contact info@cancerappy.com